Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
Early cranial stereotactic radiotherapy (SRT) administered with first-line osimertinib was associated with improved intracranial control and survival outcomes in patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
A recent study presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer suggests that early cranial stereotactic radiotherapy (SRT) may improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) and limited brain metastases when combined with first-line osimertinib treatment.
The retrospective analysis of patients who received osimertinib alone or with early cranial SRT found that achieving an intracranial complete response to osimertinib did not necessarily correlate with improved overall survival. Patients who did not achieve an intracranial complete response appeared to benefit more from SRT, particularly when administered in a consolidative manner.
The research indicates that early cranial SRT may enhance intracranial control and survival outcomes when used alongside osimertinib in this patient population, but further research through a randomized clinical trial is needed to confirm these findings.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
